<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01632995</url>
  </required_header>
  <id_info>
    <org_study_id>PrEP Demonstration Project</org_study_id>
    <secondary_id>11879</secondary_id>
    <nct_id>NCT01632995</nct_id>
  </id_info>
  <brief_title>Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics</brief_title>
  <official_title>Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure
      prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of emtricitabine
      (FTC)/tenofovir disoproxil fumarate (TDF), administered at sexually transmitted disease (STD)
      clinics and a community health center in the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A previous study (iPrEx) showed that daily PrEP with FTC/TDF provided with a comprehensive
      package of prevention services is effective in preventing HIV infection among men who have
      sex with men (MSM). The PrEP administered in that study was given in the context of a
      research setting/controlled trial, but it is important to evaluate the acceptability,
      sustainability, and safety of PrEP in a &quot;real world&quot; setting. This study will evaluate PrEP
      administered to HIV-uninfected MSM and transgender females at two STD clinics and one
      community health center in the United States.

      Each participant will receive PrEP for up to 1 year and will have up to 8 study visits. PrEP
      will consist of one fixed-dose FTC/TDF combination tablet orally each day. All participants
      will have study visits at screening, enrollment, and 4 weeks after enrollment; participants
      will continue to have visits at Weeks 12, 24, 36, 48, and 52 if they do not seroconvert.
      Participants who seroconvert will discontinue PrEP and will have a post-drug discontinuation
      visit 4 weeks after discontinuing PrEP. At most visits, participants will undergo blood,
      urine, and hair sample collection; give a medical history; undergo a physical exam; receive
      risk-reduction counseling and condoms; undergo testing for HIV and other STDs; receive study
      drugs; and undergo a pill count and adherence assessment (follow-up visits only). For
      participants who stop taking the study drug but remain in the study, urine, blood, and hair
      samples will not be collected at 12-week follow-up visits if all stop procedures have been
      completed and if there are no lab abnormalities that require additional follow-up.
      Participants will also answer questionnaires at screening, 12-week visits, and at study exit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Acceptance Rate of PrEP</measure>
    <time_frame>Measured through enrollment (Week 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Refusal Rate of PrEP</measure>
    <time_frame>Measured through enrollment (Week 0)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of PrEP Use</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
    <description>Number of study drug interruptions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of PrEP Use</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
    <description>Mean duration of interruptions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of Side Effects/Toxicities</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of PrEP Adherence by TFV-DP Levels in DBS</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Male Sexual Partners</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of PrEP Adherence by Medication Possession Ratio</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
    <description>Medication possession ratio is defined as the number of dispensed pills divided by the number of days between visits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Seroconvert</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV Drug Resistance Patterns Among Participants Who Become Infected</measure>
    <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">557</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTC 200 mg/TDF 300 mg fixed-dose combination tablet</intervention_name>
    <description>Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
    <arm_group_label>Emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be either a man who has sex with men or a transgender female

          -  Male sex (at birth)

          -  Willing and able to provide written informed consent

          -  HIV-1 uninfected, defined as having a negative rapid HIV antibody test at both
             screening visit and enrollment and a negative 4th generation antibody/antigen test at
             screening

          -  No laboratory evidence of a detectable HIV viral load (San Francisco site only)

          -  Evidence of risk of acquiring HIV-1 infection including any one of the following:

             (1) Condomless anal sex with two or more male or transgender female sex partners
             during the last 12 months; or (2) two or more episodes of anal sex with at least one
             HIV-positive partner during the last 12 months; or (3) sex with a male or transgender
             female partner and any of the following STDs diagnosed during the last 12 months or at
             screening: syphilis, rectal gonorrhea, or rectal chlamydia.

          -  Able to provide a street address of residence or phone number for themselves or two
             personal contacts who would know their whereabouts during the period of the
             demonstration project

          -  Adequate renal function: creatinine clearance of 60 ml/min or greater as estimated by
             the Cockcroft-Gault equation within 45 days of enrollment

          -  A urine dipstick with a negative or trace result for protein within 45 days of
             enrollment

          -  Fluent in English or in Spanish

        Exclusion Criteria:

          -  Signs or symptoms of acute HIV infection

          -  Previously diagnosed active and serious infections including active tuberculosis
             infection or osteomyelitis and all infections requiring parenteral antibiotic therapy
             (other than STDs requiring intramuscular injections of antibiotics); active clinically
             significant medical problems including poorly controlled cardiac disease (e.g.,
             symptoms of ischemia or congestive heart failure) or previously diagnosed malignancy
             expected to require further treatment

          -  Hepatitis B surface antigen (HBsAg) positive

          -  History of pathological bone fractures not related to trauma

          -  Receiving ongoing therapy with any of the following: investigational antiretroviral
             agents (PEP is allowed as described in the protocol), interferon (alpha, beta, or
             gamma) or interleukin (e.g., IL-2) therapy, agents with significant nephrotoxic
             potential, other agents that may inhibit or compete for elimination via active renal
             tubular secretion (e.g., probenecid), and/or other investigational agents

          -  Concomitant participation in a clinical trial using investigational agents, including
             placebo-controlled clinical trials using such agents

          -  At enrollment, has any other condition that, based on the opinion of the investigator
             or designee, would preclude provision of informed consent; make participation in the
             project unsafe; complicate interpretation of outcome data; or otherwise interfere with
             achieving the project objectives
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Liu, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>San Francisco Department of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SF City Clinic Non-Network CRS</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman Walker Non-network CRS</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami PrEP Non-Network CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.</citation>
    <PMID>21091279</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2012</study_first_submitted>
  <study_first_submitted_qc>June 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2012</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2017</results_first_posted>
  <last_update_submitted>January 30, 2017</last_update_submitted>
  <last_update_submitted_qc>January 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened and enrolled at 3 sites in the US (San Francisco, Miami, Washington DC). Enrollment began on October 1, 2012 and ended February 10, 2015.</recruitment_details>
      <pre_assignment_details>As this PrEP Demonstration project assessed acceptance of PrEP, all participants assessed for participation are included in the &quot;start&quot; category, and those who enrolled and initiated PrEP are indicated as a separate milestone.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-screening to Enrollment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1069"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="557"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="512"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Main Study Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="557"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="557"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="27" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Acceptance Rate of PrEP</title>
        <time_frame>Measured through enrollment (Week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Assessed for Participation</title>
            <description>All participants who were assessed for study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Acceptance Rate of PrEP</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1069"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Potentially eligible clients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants enrolled</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="557"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Refusal Rate of PrEP</title>
        <time_frame>Measured through enrollment (Week 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Participants Assessed for Participation</title>
            <description>All participants who were assessed for study participation</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Refusal Rate of PrEP</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1069"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Potentially eligible clients</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Declined participation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of PrEP Use</title>
        <description>Number of study drug interruptions</description>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of PrEP Use</title>
          <description>Number of study drug interruptions</description>
          <units>interruptions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of PrEP Use</title>
        <description>Mean duration of interruptions</description>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of PrEP Use</title>
          <description>Mean duration of interruptions</description>
          <units>Days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Side Effects/Toxicities</title>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Side Effects/Toxicities</title>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine elevations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of PrEP Adherence by TFV-DP Levels in DBS</title>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <population>DBS testing was performed in approximately 100 randomly selected participants per site, and among all African American and transgender participants, who were underrepresented in the overall sample</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With DBS Testing</title>
            <description>All study participants who had at least 1 DBS result</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PrEP Adherence by TFV-DP Levels in DBS</title>
          <population>DBS testing was performed in approximately 100 randomly selected participants per site, and among all African American and transgender participants, who were underrepresented in the overall sample</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% with protective TFV-DP levels at week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with protective TFV-DP levels at week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with protective TFV-DP levels at week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with protective TFV-DP levels at week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% with protective TFV-DP levels at week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Male Sexual Partners</title>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Male Sexual Partners</title>
          <units>partners</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean Anal sex partners at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" lower_limit="0" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Anal sex partners at week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="0" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement of PrEP Adherence by Medication Possession Ratio</title>
        <description>Medication possession ratio is defined as the number of dispensed pills divided by the number of days between visits</description>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <population>Mean PrEP adherence by medication possession ratio</population>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of PrEP Adherence by Medication Possession Ratio</title>
          <description>Medication possession ratio is defined as the number of dispensed pills divided by the number of days between visits</description>
          <population>Mean PrEP adherence by medication possession ratio</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Seroconvert</title>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Seroconvert</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute HIV infection at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV seroconversion during follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measurement of HIV Drug Resistance Patterns Among Participants Who Become Infected</title>
        <time_frame>Participants were followed for 48 weeks, or up to the point of early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
            <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of HIV Drug Resistance Patterns Among Participants Who Become Infected</title>
          <units>participant with acquired HIV resistance</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF)</title>
          <description>All study participants will be assigned to this arm and will receive one FTC/TDF tablet orally once a day.
FTC 200 mg/TDF 300 mg fixed-dose combination tablet: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension / Hypertensive crisis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation and/or attempt, bipolar disorder, or anxiety</sub_title>
                <description>Assessed as not related to study drug</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bone fracture</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine elevation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="13" subjects_at_risk="557"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Albert Liu, Clinical Research Director</name_or_title>
      <organization>Bridge HIV, San Francisco Department of Public Health</organization>
      <phone>415-437-7408</phone>
      <email>albert.liu@sfdph.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

